1. European Medicines Agency. Repatha (evolocumab): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003766/WC500191398.pdf . Accessed 4 Aug 2015.
2. Amgen, Astellas Pharma. Amgen and Astellas announce Japan alliance [media release]. 29 May 2013. http://www.amgen.com .
3. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–98.
4. Emery MG, Gibbs JP, Slatter JG, et al. Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034]. Clin Pharmacol Ther. 2015;97:S69.
5. Gibbs JP, Grover A, Emery MG, et al. Impact of target-mediated elimination on evolocumab dose and regimen [abstract no. 422]. In: European Atherosclerosis Society Annual Congress 2015. 2015.